Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Mixture · Mixture or extract
Detailed molecular class: Gonadotropin mixture
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
FSH/LH activity in ovarian stimulation.
Evidence and critical reading
Reported scientific and empirical uses
Fertility and reproduction
Menotropins are a gonadotropin mixture, not one peptide or a community stack.
Human evidence
Menopur has a defined assisted-reproduction indication.
Preclinical evidence
Endocrine clinical use does not validate wellness blends.
Critical reading and limitations
Reproductive stimulation requires a specific population/product; data do not prove general hormonal wellness.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
US: Menopur product-specific labeling; not a general approval of supplier hMG.
Adverse effects and unknowns
Ovarian hyperstimulation, thromboembolism and multiple gestation are material risks. Contraindications include pregnancy, certain hormone-dependent tumors and unexplained uterine bleeding. Human drug-interaction studies were not conducted per label.
Ovarian hyperstimulation, thromboembolism and multiple gestation are material Menopur risks.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
menotropins · 171 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07873502 · HMG Treatment Reduces Sperm DNA FragmentationRegistry status: CompletedLast update posted: October 14, 2026Query verification: October 16, 2026
NCT07216742 · Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.Registry status: RecruitingLast update posted: September 24, 2026Query verification: October 16, 2026
NCT07340827 · A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)Registry status: RecruitingLast update posted: September 8, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- REG-HMG
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026